Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug552 | Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy Wiki | 1.00 |
drug346 | Arm exercise electrocardiographic stress test Wiki | 1.00 |
drug3305 | Regadenoson myocardial perfusion imaging stress test Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.09 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D055371 | Acute Lung Injury NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is a 5-year clinical trial to evaluate whether arm exercise electrocardiographic (ECG) stress testing without or with coronary artery calcium scoring (-/+ CAC) is non-inferior to treadmill ECG stress testing -/+ CAC and pharmacologic myocardial perfusion imaging as an initial evaluation to detect obstructive coronary artery disease, determined by cardiac computed tomographic angiography (CTA) and to predict clinical outcome, defined by a primary clinical endpoint of the composite of cardiovascular (CV) mortality, myocardial infarction, and 90-day post-stress test coronary artery revascularization and secondary clinical endpoints of all-cause mortality and CV mortality.
Description: Death from a cardiovascular cause, occurrence of myocardial infarction, and 90-day post-stress test coronary artery revascularization by any technique determined from VA, National Death Index, Missouri Health and Human Services, and non-VA medical records, and patient follow-up information.
Measure: Composite of cardiovascular mortality, myocardial infarction, and 90-day post-stress test coronary artery revascularization Time: 5 yearsDescription: Death from any cause determined from VA, Social Security, and National Death Index records and patient follow-up information.
Measure: All-cause mortality Time: 5 yearsDescription: Death from a cardiovascular cause determined from VA, Missouri Health and Human Services, and National Death Index records and patient follow-up information.
Measure: Cardiovascular mortality Time: 5 yearsDescription: Severely (at least 70%) or completely occluded epicardial coronary arteries or grafts determined by cardiac computed tomographic angiography or invasive coronary arteriography
Measure: Obstructive coronary artery disease Time: 5 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports